GDP366

Cat. No.:	HY-U00177
CAS No.:	501698-03-9
Molecular Formula:	$C_{20}H_{17}N_5OS$
Molecular Weight:	375.45
Target:	Survivin
Pathway:	Apoptosis
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 62.5 mg/mL (166.47 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6635 mL	13.3174 mL	26.6347 mL
	5 mM	0.5327 mL	2.6635 mL	5.3269 mL
	10 mM	0.2663 mL	1.3317 mL	2.6635 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (5.54 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

GDP366, a dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells.

IC_{50} & Target

Survivin[1]
Op18[1]

In Vitro

GDP366 potently and selectively inhibits the expression of both survivin and Op18. GDP366 decreass both the mRNA and protein levels of survivin and Op18. This inhibitory effect is not dependent on the status of p53 and p21 although GDP366 potently increases p53 and p21 levels. GDP366 significantly inhibits the growth of tumor cells in vitro and in vivo (nude mouse model) without rapid induction of apoptosis. GDP366 induces polyploidy in multiple types of cancer cell lines. GDP366 increases chromosomal instability, and induces cellular senescence by inhibiting telomerase activity[1].

CUSTOMER VALIDATION

- Invest New Drugs. 2021 Jan 21.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Shi X, et al. GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Cancer Biol Ther. 2010 Apr 15;9(8):640-50.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA